Aberdeen Group plc Increases Stake in Revvity Inc. $RVTY

Key Points

• Aberdeen Group plc increased its stake in Revvity Inc. by 141.8% in the first quarter, owning over 106,000 shares worth approximately $11.15 million.
• Revvity reported a quarterly EPS of $1.18, exceeding estimates, and set a forecast for FY 2025 EPS at 4.850-4.950.
• The company recently declared a quarterly dividend of $0.07 per share, reflecting an annual yield of 0.3% and a payout ratio of 11.86%.

Aberdeen Group plc increased its holdings in Revvity Inc. (NYSE:RVTY - Free Report) by 141.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 106,041 shares of the company's stock after buying an additional 62,192 shares during the period. Aberdeen Group plc owned 0.09% of Revvity worth $11,149,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Optiver Holding B.V. purchased a new position in Revvity during the fourth quarter valued at approximately $33,000. Quarry LP raised its position in Revvity by 45.7% during the fourth quarter. Quarry LP now owns 303 shares of the company's stock valued at $34,000 after purchasing an additional 95 shares in the last quarter. Vermillion Wealth Management Inc. purchased a new position in shares of Revvity during the 4th quarter valued at about $41,000. New Age Alpha Advisors LLC bought a new stake in Revvity in the first quarter worth $44,000. Finally, Continuum Advisory LLC lifted its position in Revvity by 39.3% in the fourth quarter. Continuum Advisory LLC now owns 471 shares of the company's stock valued at $53,000 after purchasing an additional 133 shares during the last quarter. Hedge funds and other institutional investors own 86.65% of the company's stock.

Revvity Trading Down 2.2%

RVTY traded down $2.03 during trading on Monday, reaching $92.12. The company had a trading volume of 699,614 shares, compared to its average volume of 1,390,790. Revvity Inc. has a 52 week low of $85.12 and a 52 week high of $129.50. The company has a quick ratio of 2.75, a current ratio of 3.33 and a debt-to-equity ratio of 0.43. The business has a 50 day simple moving average of $94.49 and a 200-day simple moving average of $98.56. The stock has a market cap of $10.69 billion, a P/E ratio of 39.03, a PEG ratio of 2.53 and a beta of 0.91.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The company reported $1.18 EPS for the quarter, beating the consensus estimate of $1.14 by $0.04. The company had revenue of $720.28 million for the quarter, compared to the consensus estimate of $711.26 million. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The firm's revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.22 EPS. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. On average, equities analysts anticipate that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 17th will be issued a $0.07 dividend. The ex-dividend date is Friday, October 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. Revvity's dividend payout ratio is presently 11.86%.

Analyst Ratings Changes

A number of brokerages recently commented on RVTY. UBS Group raised Revvity from a "neutral" rating to a "buy" rating and dropped their price target for the stock from $145.00 to $115.00 in a research note on Thursday, May 1st. Bank of America dropped their price target on shares of Revvity from $116.00 to $110.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Raymond James Financial reiterated an "outperform" rating and set a $115.00 price objective (down previously from $120.00) on shares of Revvity in a research report on Tuesday, July 29th. Robert W. Baird decreased their price target on shares of Revvity from $127.00 to $125.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 29th. Finally, JPMorgan Chase & Co. lowered their price objective on Revvity from $120.00 to $100.00 and set a "neutral" rating on the stock in a research report on Tuesday, April 29th. Ten investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, Revvity currently has an average rating of "Moderate Buy" and a consensus target price of $120.07.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.